Xconomy’s Digital Events →
▾
Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it’s now looking to tap the public markets to finance tests of the technology in humans.
In paperwork submitted to... Read more »
The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to 免费翻国外墙的app with publicly traded Arya Sciences Acquisition Corp II.
If... Read more »
Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level.
Sangamo on Thursday announced that Novartis (NYSE: NVS) had agreed to shell out... 能上国外网的免费加速器
AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients.
On Thursday, Cambridge, MA-based AlloVir (NASDAQ:... Read more »
Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings.
The La Jolla, CA-based company, which is developing drugs for cancer and a rare respiratory disease, has again applied... Read more »
As the Alzheimer’s disease world continues to closely follow the development of therapies that break up clumps of beta amyloid on patients’ brains, Roche is placing a bet on another approach via a deal that secures rights to a clinical-stage UCB... Read more »
After receiving and reviewing nearly 600 entries spanning 10 award categories, Xconomy is thrilled to announce the 2023 Xconomy National Awards Finalists.
Since 2017, the mission of Xconomy’s annual awards programs has been to provide the industry a moment to... 能上国外网的免费加速器
The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.
Omega is developing technology that... Read more »
Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal degeneration, made its public debut Wednesday with a $73 million... Read more »
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational... 免费跨国加速器
Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that candidate takes the same tack as other companies trying to address... Read more »
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors.
The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that... Read more »
AstraZeneca’s partnership with Daiichi Sankyo led to FDA approval of an antibody cancer drug late last year. Now the British pharmaceutical giant is paying $1 billion up front to join forces on another antibody drug addressing a different cancer target.
The... Read more »
The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of... Read more »
The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy.
Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed... Read more »
EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. But it offered few specifics about how... 国外免费加速器下载
The FDA has 免费翻国外墙的app a hold on clinical trials for an experimental CymaBay Therapeutics drug in three liver diseases, clearing the way for tests to resume in all of them. But the company won’t be pressing forward in the biggest one,... Read more »
[Corrected 7/23/20, 10:13 am. See below.] Jazz Pharmaceuticals has received FDA approval for a narcolepsy drug that it has developed as a lower-sodium successor to its biggest moneymaker, a treatment that was first approved in 2002 to reduce attacks of... Read more »
It’s not enough for a cell or gene therapy to reach a cell, it must also get inside it to access most of the validated drug targets. Vesigen Therapeutics is developing technology that could best other approaches at penetrating the cellular... Read more »
Illumina led the genomics revolution, developing tools that have changed how scientists discover drugs and how clinicians treat patients. Startup Seer is making the case that its technology for analyzing the proteome—the complement of proteins that cells, tissues, and organs produce—will... Read more »
Olema Oncology has raised $54 million to advance its lead drug candidate into human tests, having been working in stealth since 2007 to develop a daily pill to treat women with breast cancer whose disease is driven by the hormone estrogen.
San Francisco-based... Read more »
奇游电竞加速器 新游热游毫秒响应 72小时免费试用【官方网站】:奇游电竞加速器,电竞级网络加速,超低延迟/秒级响应/拒绝丢包,完美加速绝地求生、gta5、csgo、彩虹六号、战地5等游戏,新游热 ...
Freeline is raising cash to ensure that its lead program, a prospective hemophilia B gene... Read more »
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Sponsored · Video
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
